G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS
Koichi Takahashi,Feng Wang,Seth Sahil,Jianhua Zhang,Curtis Gumbs,Ghayas C. Issa,Christopher B. Benton,Sherry Pierce,Elias Jabbour,Naval Daver,Tapan M. Kadia,Courtney D. DiNardo,Hagop M. Kantarjian,Andrew Futreal,Guillermo Garcia-Manero +14 more
TL;DR: High-confidence driver mutations in myelodysplastic syndromes patients with untreated MDS were detected in 39 genes by sequencing, and patients who were found to carry 4 or more driver mutations had significantly poor response to HMA therapy compared to patients with less than 4 driver mutations.
Journal ArticleDOI
Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Guillermo Garcia-Manero,Francesco Paolo Tambaro,Nebiyou Bekele,Elias Jabbour,Gautam Borthakur,Farhad Ravandi,Marina Konopleva,Tapan M. Kadia,Jorge E. Cortes,Hui Yang,Mark Brandt,Sherry Pierce,Willie Newsome,Hagop M. Kantarjian +13 more
TL;DR: A phase I trial of Vor and Ida demonstrated that doses of vorinostat up to 500 mg po TID daily × 3 are safe in combination with Ida, and a phase II trial to study the safety and activity of the triple combination in patients with AML or higher-risk MDS was developed.
Journal ArticleDOI
Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)
Hagop M. Kantarjian,Susan O'Brien,Farhad Ravandi,Jorge E. Cortes,Jianqin Shan,John M. Bennett,Alan F. List,Pierre Fenaux,Guillermo Garcia-Manero +8 more
TL;DR: A new prognostic model was developed and validated for MDS, which accounts for all MDS or CMML cases, regardless of prior therapy, which has been validated in an independent test group and was shown to be superior to IPSS.
Journal ArticleDOI
A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Elias Jabbour,Nicholas J. Short,Xuelin Huang,Abhishek Maiti,Tapan M. Kadia,Naval Daver,Gautam Borthakur,Courtney D. DiNardo,Naveen Pemmaraju,Koji Sasaki,Zeev Estrov,Srdan Verstovsek,Farhad Ravandi,Yesid Alvarado,Mikkael A. Sekeres,Rami S. Komrokji,David P. Steensma,Amy E. DeZern,Gail J. Roboz,Darla Miller,Xiao Dong,Hagop M. Kantarjian,Guillermo Garcia-Manero +22 more
TL;DR: Both low-dose decitabine and azacitidine in pts with lower-risk MDS were overall well-tolerated and there was a trend toward prolonged EFS with DAC compared to AZA.
Journal ArticleDOI
Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase
Koji Sasaki,Hagop M. Kantarjian,Elias Jabbour,Susan O'Brien,Farhad Ravandi,Marina Konopleva,Gautam Borthakur,William G. Wierda,Naval Daver,Koichi Takahashi,Preetesh Jain,Jeffrey Skinner,Mary Beth Rios,Sherry Pierce,Guillermo Garcia-Manero,Jorge E. Cortes +15 more
TL;DR: This study introduces a prototype of AI to predict outcome such as achievement of major molecular response (MMR) within 1 year of the start of tyrosine kinase inhibitor (TKI) in 630 patients with newly diagnosed CML-CP.